Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT05374590 | Evaluating Long-term Safety of Efgartigimod Administered Intravenously and Efgartigimod PH20 Administered Subcutaneously in Children With Generalized Myasthenia Gravis | PHASE2 | ENROLLING BY_INVITATION | 12 | — | — | Aug 18, 2022 | Sep 1, 2029 | Apr 23, 2026 | 16 | United States, Belgium +8 |
AE : adverse event; SAE : serious adverse event; AESI : adverse event of special interest
| Arm | Type | Description |
|---|---|---|
| Efgartigimod or Efgartigimod PH20 SC | EXPERIMENTAL | Patients receiving Efgartigimod IV treatment or Efgartigimod PH 20 SC treatment |
| Name | Type | Description |
|---|---|---|
| Efgartigimod IV or Efgartigimod PH20 SC | BIOLOGICAL | Intravenous infusion of Efgartigimod or Subcutaneous injection of Efgartigimod PH20 SC |
Inclusion Criteria: * The participant completed ARGX-113-2006, defined as: 1. The participant reached End of Trial in trial ARGX-113-2006 or End of Study in ARGX-113-2207 and agreed to participate in the ARGX-113-2008 trial. 2. The participant qualifies for retreatment in trial ARGX-113-2006, ...